Loading…
Loading…
EQUITY / NASDAQ · XNGS
Amylyx Pharmaceuticals, Inc.
01 / RESEARCH
8 financial reports are available for research.
Start research ↗29.1 USD · 0%
Observed: Sep 30, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
09/30/2026 · 29.1 USD · Volume 1,306,941
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Cash and cash equivalents | 49,326,000 USD | 58,085,000 USD | -15.08% |
| Net income | -43,423,000 USD | -41,443,000 USD | — |
| Operating profit | -45,693,000 USD | -42,857,000 USD | — |
| Total assets | 264,564,000 USD | — | — |
| Total equity | 239,167,000 USD | 167,877,000 USD | +42.47% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2026 / Quarter 2ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD | 2025 / Year endConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 3ConsolidatedUnits · USD | 2025 / Quarter 2ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 49,326,000 USD | — | — | 226,651,000 USD | 226,651,000 USD | 225,178,000 USD | — | 58,085,000 USD |
| Net incomeIncome statement | -43,423,000 USD | -84,707,000 USD | -41,284,000 USD | — | -144,735,000 USD | -34,386,000 USD | -111,736,000 USD | -41,443,000 USD |
| Operating profitIncome statement | -45,693,000 USD | -89,472,000 USD | — | — | -153,291,000 USD | -36,027,000 USD | -116,686,000 USD | -42,857,000 USD |
| Total assetsBalance sheet | 264,564,000 USD | — | — | 332,645,000 USD | 332,645,000 USD | 362,741,000 USD | — | — |
| Total equityBalance sheet | 239,167,000 USD | — | 273,161,000 USD | 305,259,000 USD | 305,259,000 USD | 331,996,000 USD | — | 167,877,000 USD |
| Total liabilitiesBalance sheet | 25,397,000 USD | — | — | 27,386,000 USD | 27,386,000 USD | 30,745,000 USD | — | — |
| Capital expendituresCash flow statement | — | 30,000 USD | — | — | 138,000 USD | — | 52,000 USD | — |
| Financing cash flowCash flow statement | — | 4,696,000 USD | — | — | 257,029,000 USD | — | 257,237,000 USD | — |
| Investing cash flowCash flow statement | — | -113,535,000 USD | — | — | 14,039,000 USD | — | -15,429,000 USD | — |
| Operating cash flowCash flow statement | — | -68,306,000 USD | — | — | -123,343,000 USD | — | -95,440,000 USD | — |
| RevenueIncome statement | — | — | — | — | 0 USD | 0 USD | 0 USD | — |
| Report source | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 08/06/2026 | Open report ↗ Published: 03/03/2026 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 11/06/2025 | Open report ↗ Published: 08/06/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.